Skip to main content
Erschienen in: Head and Neck Pathology 2/2017

20.06.2016 | Original Paper

Nuclear β-Catenin Expression is Frequent in Sinonasal Hemangiopericytoma and Its Mimics

verfasst von: Vickie Y. Jo, Christopher D. M. Fletcher

Erschienen in: Head and Neck Pathology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Sinonasal hemangiopericytoma (HPC) is a tumor showing pericytic myoid differentiation and which arises in the nasal cavity and paranasal sinuses. CTNNB1 mutations appear to be a consistent aberration in sinonasal HPC, and nuclear expression of β-catenin has been reported. Our aim was to evaluate the frequency of β-catenin expression in sinonasal HPC and its histologic mimics in the upper aerodigestive tract. Cases were retrieved from the surgical pathology and consultation files. Immunohistochemical staining for β-catenin was performed on 50 soft tissue tumors arising in the sinonasal tract or oral cavity, and nuclear staining was recorded semiquantitatively by extent and intensity. Nuclear reactivity for β-catenin was present in 19/20 cases of sinonasal HPC; 17 showed moderate-to-strong multifocal or diffuse staining, and 2 had moderate focal nuclear reactivity. All solitary fibrous tumors (SFT) (10/10) showed focal-to-multifocal nuclear staining, varying from weak to strong in intensity. Most cases of synovial sarcoma (9/10) showed nuclear β-catenin expression in the spindle cell component, ranging from focal-weak to strong-multifocal. No cases of myopericytoma (0/10) showed any nuclear β-catenin expression. β-catenin expression is prevalent in sinonasal HPC, but is also frequent in SFT and synovial sarcoma. Our findings indicate that β-catenin is not a useful diagnostic tool in the evaluation of spindle cell tumors with a prominent hemangiopericytoma-like vasculature in the sinonasal tract and oral cavity, and that definitive diagnosis relies on the use of a broader immunohistochemical panel.
Literatur
1.
Zurück zum Zitat El-Naggar AK, Batsakis JG, Garcia GM, et al. Sinonasal hemangiopericytomas. A clinicopathologic and DNA content study. Arch Otolaryngol Head Neck Surg. 1992;118:134–7.CrossRefPubMed El-Naggar AK, Batsakis JG, Garcia GM, et al. Sinonasal hemangiopericytomas. A clinicopathologic and DNA content study. Arch Otolaryngol Head Neck Surg. 1992;118:134–7.CrossRefPubMed
2.
Zurück zum Zitat Tse LL, Chan JK. Sinonasal haemangiopericytoma-like tumour: a sinonasal glomus tumour or a haemangiopericytoma? Histopathology. 2002;40:510–7.CrossRefPubMed Tse LL, Chan JK. Sinonasal haemangiopericytoma-like tumour: a sinonasal glomus tumour or a haemangiopericytoma? Histopathology. 2002;40:510–7.CrossRefPubMed
3.
Zurück zum Zitat Thompson LD, Miettinen M, Wenig BM. Sinonasal-type hemangiopericytoma: a clinicopathologic and immunophenotypic analysis of 104 cases showing perivascular myoid differentiation. Am J Surg Pathol. 2003;27:737–49.CrossRefPubMed Thompson LD, Miettinen M, Wenig BM. Sinonasal-type hemangiopericytoma: a clinicopathologic and immunophenotypic analysis of 104 cases showing perivascular myoid differentiation. Am J Surg Pathol. 2003;27:737–49.CrossRefPubMed
4.
Zurück zum Zitat Haller F, Bieg M, Moskalev EA, et al. Recurrent mutations within the amino-terminal region of beta-catenin are probable key molecular driver events in sinonasal hemangiopericytoma. Am J Pathol. 2015;185:563–71.CrossRefPubMed Haller F, Bieg M, Moskalev EA, et al. Recurrent mutations within the amino-terminal region of beta-catenin are probable key molecular driver events in sinonasal hemangiopericytoma. Am J Pathol. 2015;185:563–71.CrossRefPubMed
5.
Zurück zum Zitat Lasota J, Felisiak-Golabek A, Aly FZ, et al. Nuclear expression and gain-of-function beta-catenin mutation in glomangiopericytoma (sinonasal-type hemangiopericytoma): insight into pathogenesis and a diagnostic marker. Mod Pathol. 2015;28:715–20.CrossRefPubMed Lasota J, Felisiak-Golabek A, Aly FZ, et al. Nuclear expression and gain-of-function beta-catenin mutation in glomangiopericytoma (sinonasal-type hemangiopericytoma): insight into pathogenesis and a diagnostic marker. Mod Pathol. 2015;28:715–20.CrossRefPubMed
7.
Zurück zum Zitat Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–27.CrossRefPubMedPubMedCentral Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173:1518–27.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Salas S, Chibon F, Noguchi T, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer. 2010;49:560–8.PubMed Salas S, Chibon F, Noguchi T, et al. Molecular characterization by array comparative genomic hybridization and DNA sequencing of 194 desmoid tumors. Genes Chromosomes Cancer. 2010;49:560–8.PubMed
9.
Zurück zum Zitat Kawahara A, Harada H, Abe H, et al. Nuclear beta-catenin expression in basal cell adenomas of salivary gland. J Oral Pathol Med. 2011;40:460–6.CrossRefPubMed Kawahara A, Harada H, Abe H, et al. Nuclear beta-catenin expression in basal cell adenomas of salivary gland. J Oral Pathol Med. 2011;40:460–6.CrossRefPubMed
10.
Zurück zum Zitat Lazar AJ, Calonje E, Grayson W, et al. Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J Cutan Pathol. 2005;32:148–57.CrossRefPubMed Lazar AJ, Calonje E, Grayson W, et al. Pilomatrix carcinomas contain mutations in CTNNB1, the gene encoding beta-catenin. J Cutan Pathol. 2005;32:148–57.CrossRefPubMed
11.
Zurück zum Zitat Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–11.CrossRefPubMedPubMedCentral Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47:505–11.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 2006;25:7531–7.CrossRefPubMed Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene. 2006;25:7531–7.CrossRefPubMed
14.
Zurück zum Zitat Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene. 2002;21:7981–90.CrossRefPubMed Moreno-Bueno G, Hardisson D, Sanchez C, et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene. 2002;21:7981–90.CrossRefPubMed
15.
16.
Zurück zum Zitat Assie G, Letouze E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607–12.CrossRefPubMed Assie G, Letouze E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607–12.CrossRefPubMed
17.
Zurück zum Zitat Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2–STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45:180–5.CrossRefPubMedPubMedCentral Robinson DR, Wu YM, Kalyana-Sundaram S, et al. Identification of recurrent NAB2–STAT6 gene fusions in solitary fibrous tumor by integrative sequencing. Nat Genet. 2013;45:180–5.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2–STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45:131–2.CrossRefPubMedPubMedCentral Chmielecki J, Crago AM, Rosenberg M, et al. Whole-exome sequencing identifies a recurrent NAB2–STAT6 fusion in solitary fibrous tumors. Nat Genet. 2013;45:131–2.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Doyle LA, Vivero M, Fletcher CD, et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27:390–5.CrossRefPubMed Doyle LA, Vivero M, Fletcher CD, et al. Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics. Mod Pathol. 2014;27:390–5.CrossRefPubMed
20.
Zurück zum Zitat Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2–STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013;125:651–8.CrossRefPubMed Schweizer L, Koelsche C, Sahm F, et al. Meningeal hemangiopericytoma and solitary fibrous tumors carry the NAB2–STAT6 fusion and can be diagnosed by nuclear expression of STAT6 protein. Acta Neuropathol. 2013;125:651–8.CrossRefPubMed
21.
Zurück zum Zitat Rakheja D, Molberg KH, Roberts CA, et al. Immunohistochemical expression of beta-catenin in solitary fibrous tumors. Arch Pathol Lab Med. 2005;129:776–9.PubMed Rakheja D, Molberg KH, Roberts CA, et al. Immunohistochemical expression of beta-catenin in solitary fibrous tumors. Arch Pathol Lab Med. 2005;129:776–9.PubMed
22.
Zurück zum Zitat Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18:68–74.CrossRefPubMed Ng TL, Gown AM, Barry TS, et al. Nuclear beta-catenin in mesenchymal tumors. Mod Pathol. 2005;18:68–74.CrossRefPubMed
23.
Zurück zum Zitat Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 2007;51:509–14.CrossRefPubMed Carlson JW, Fletcher CD. Immunohistochemistry for beta-catenin in the differential diagnosis of spindle cell lesions: analysis of a series and review of the literature. Histopathology. 2007;51:509–14.CrossRefPubMed
24.
Zurück zum Zitat Foo WC, Cruise MW, Wick MR, et al. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clin Pathol. 2011;135:839–44.CrossRefPubMed Foo WC, Cruise MW, Wick MR, et al. Immunohistochemical staining for TLE1 distinguishes synovial sarcoma from histologic mimics. Am J Clin Pathol. 2011;135:839–44.CrossRefPubMed
25.
Zurück zum Zitat Horvai AE, Kramer MJ, O’Donnell R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med. 2006;130:792–8.PubMed Horvai AE, Kramer MJ, O’Donnell R. Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med. 2006;130:792–8.PubMed
26.
Zurück zum Zitat Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 1995;14:2333–40.PubMedPubMedCentral Crew AJ, Clark J, Fisher C, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 1995;14:2333–40.PubMedPubMedCentral
27.
Zurück zum Zitat Barham W, Frump AL, Sherrill TP, et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov. 2013;3:1286–301.CrossRefPubMed Barham W, Frump AL, Sherrill TP, et al. Targeting the Wnt pathway in synovial sarcoma models. Cancer Discov. 2013;3:1286–301.CrossRefPubMed
28.
Zurück zum Zitat Trautmann M, Sievers E, Aretz S, et al. SS18–SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene. 2014;33:5006–16.CrossRefPubMed Trautmann M, Sievers E, Aretz S, et al. SS18–SSX fusion protein-induced Wnt/beta-catenin signaling is a therapeutic target in synovial sarcoma. Oncogene. 2014;33:5006–16.CrossRefPubMed
29.
Zurück zum Zitat Cironi L, Petricevic T, Fernandes Vieira V, et al. The fusion protein SS18–SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma. Sci Rep. 2016;6:22113.CrossRefPubMedPubMedCentral Cironi L, Petricevic T, Fernandes Vieira V, et al. The fusion protein SS18–SSX1 employs core Wnt pathway transcription factors to induce a partial Wnt signature in synovial sarcoma. Sci Rep. 2016;6:22113.CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Dahlen A, Fletcher CD, Mertens F, et al. Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). Am J Pathol. 2004;164:1645–53.CrossRefPubMedPubMedCentral Dahlen A, Fletcher CD, Mertens F, et al. Activation of the GLI oncogene through fusion with the beta-actin gene (ACTB) in a group of distinctive pericytic neoplasms: pericytoma with t(7;12). Am J Pathol. 2004;164:1645–53.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Dahlen A, Mertens F, Mandahl N, et al. Molecular genetic characterization of the genomic ACTB–GLI fusion in pericytoma with t(7;12). Biochem Biophys Res Commun. 2004;325:1318–23.CrossRefPubMed Dahlen A, Mertens F, Mandahl N, et al. Molecular genetic characterization of the genomic ACTB–GLI fusion in pericytoma with t(7;12). Biochem Biophys Res Commun. 2004;325:1318–23.CrossRefPubMed
34.
Zurück zum Zitat Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;29:653–9.CrossRefPubMed Bhattacharya B, Dilworth HP, Iacobuzio-Donahue C, et al. Nuclear beta-catenin expression distinguishes deep fibromatosis from other benign and malignant fibroblastic and myofibroblastic lesions. Am J Surg Pathol. 2005;29:653–9.CrossRefPubMed
Metadaten
Titel
Nuclear β-Catenin Expression is Frequent in Sinonasal Hemangiopericytoma and Its Mimics
verfasst von
Vickie Y. Jo
Christopher D. M. Fletcher
Publikationsdatum
20.06.2016
Verlag
Springer US
Erschienen in
Head and Neck Pathology / Ausgabe 2/2017
Elektronische ISSN: 1936-0568
DOI
https://doi.org/10.1007/s12105-016-0737-2

Weitere Artikel der Ausgabe 2/2017

Head and Neck Pathology 2/2017 Zur Ausgabe

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Open Access Biomarker Leitthema

Um auch an kleinen Gewebeproben zuverlässige und reproduzierbare Ergebnisse zu gewährleisten ist eine strenge Qualitätskontrolle in jedem Schritt des Arbeitsablaufs erforderlich. Eine nicht ordnungsgemäße Prüfung oder Behandlung des …

Vergleichende Pathologie in der onkologischen Forschung

Pathologie Leitthema

Die vergleichende experimentelle Pathologie („comparative experimental pathology“) ist ein Fachbereich an der Schnittstelle von Human- und Veterinärmedizin. Sie widmet sich der vergleichenden Erforschung von Gemeinsamkeiten und Unterschieden von …

Gastrointestinale Stromatumoren

Open Access GIST CME-Artikel

Gastrointestinale Stromatumoren (GIST) stellen seit über 20 Jahren ein Paradigma für die zielgerichtete Therapie mit Tyrosinkinaseinhibitoren dar. Eine elementare Voraussetzung für eine mögliche neoadjuvante oder adjuvante Behandlung bei …

Personalisierte Medizin in der Onkologie

Aufgrund des erheblichen technologischen Fortschritts in der molekularen und genetischen Diagnostik sowie zunehmender Erkenntnisse über die molekulare Pathogenese von Krankheiten hat in den letzten zwei Jahrzehnten ein grundlegender …